Drug Profile

TSG 01

Alternative Names: TSG-01

Latest Information Update: 11 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Hongyitang Biopharmaceutical Technology
Class Ginsenosides; Heart failure therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Chronic heart failure

Most Recent Events

04 Mar 2023 Efficacy and adverse events data from phase II trial for Chronic heart failure presented at the 72nd Annual Scientific Session of the American College of Cardiology (ACC-2023)
13 Oct 2022 TSG 01 is still in phase II trials for Chronic heart failure in China (Shanghai Hongyitang Biopharmaceutical Technology, October 2022)
07 May 2020 Phase-II clinical trials in Chronic heart failure in China (PO) (NCT04515290)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com